Article Abstract

Targeting Notch signalling pathway of cancer stem cells

Authors: Vandana Venkatesh, Raghu Nataraj, Gopenath S. Thangaraj, Murugesan Karthikeyan, Ashok Gnanasekaran, Shanmukhappa B. Kaginelli, Gobianand Kuppanna, Chandrashekrappa Gowdru Kallappa, Kanthesh M. Basalingappa


Cancer stem cells (CSCs) have been defined as cells within tumor that possess the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumor. CSCs have been increasingly identified in blood cancer, prostate, ovarian, lung, melanoma, pancreatic, colon, brain and many more malignancies. CSCs have slow growth rate and are resistant to chemotherapy and radiotherapy that lead to the failure of traditional current therapy. Eradicating the CSCs and recurrence, is promising aspect for the cure of cancer. The CSCs like any other stem cells activate the signal transduction pathways that involve the development and tissue homeostasis, which include Notch signaling pathway. The new treatment targets these pathway that control stem-cell replication, survival and differentiation that are under development. Notch inhibitors either single or in combination with chemotherapy drugs have been developed to treat cancer and its recurrence. This approach of targeting signaling pathway of CSCs represents a promising future direction for the therapeutic strategy to cure cancer.